购物车
全部删除
您的购物车当前为空
别名 卡比吗唑, 卡比马唑, Neomercazole, Carbimazol, Athyromazole
Carbimazole (Athyromazole) 是咪唑类甲状腺拮抗试剂,在体内快速转化为 MMI 而发挥作用,在体外可转化为甲咪唑,可用于 Graves 病的研究。

Carbimazole (Athyromazole) 是咪唑类甲状腺拮抗试剂,在体内快速转化为 MMI 而发挥作用,在体外可转化为甲咪唑,可用于 Graves 病的研究。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 200 mg | ¥ 128 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 248 | 现货 |
Carbimazole 相关产品
| 产品描述 | Carbimazole (Athyromazole) is an Imidazolium thyroid antagonist, which is rapidly transformed into MMI in vivo and can be converted into methidazole in vitro, and can be used in the study of Graves' disease. |
| 体内活性 | Carbimazole被人体吸收后转化为甲巯咪唑,产生抗甲状腺作用,作用于抗甲亢(过度产生甲状腺激素)和甲状腺毒症(甲状腺炎症)。 |
| 激酶实验 | In vitro kinase assays: with purified proteins, recombinant S6 protein and recombinant active P70S6K are incubated in 1x kinase buffer with various amount of HCQ or RAD001 in the presence (25 μM) or absence of ATP for 30 minutes at 30°C. Total and phosphorylated S6 at ser235/236 and ser240/244 are detected by western analysis using phosphospecific antibodies. Note that recombinant GST-tagged S6 (53 kd) is distinguished from endogenous S6 (32 kd) on the western blot. |
| 别名 | 卡比吗唑, 卡比马唑, Neomercazole, Carbimazol, Athyromazole |
| 分子量 | 186.23 |
| 分子式 | C7H10N2O2S |
| CAS No. | 22232-54-8 |
| Smiles | C(OCC)(=O)N1C(=S)N(C)C=C1 |
| 密度 | 1.05 |
| 颜色 | White |
| 物理性状 | Solid |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| 溶解度信息 | Ethanol: 12 mg/mL (64.44 mM), Sonication is recommended. DMSO: 60 mg/mL (322.18 mM), Sonication is recommended. H2O: < 1 mg/mL (insoluble or slightly soluble) | ||||||||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (10.74 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | ||||||||||||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
评论内容